MaxCyte, Inc. (NASDAQ:MXCT) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC cut its stake in shares of MaxCyte, Inc. (NASDAQ:MXCTGet Rating) by 2.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 334,870 shares of the company’s stock after selling 9,135 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in MaxCyte were worth $2,176,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in shares of MaxCyte by 4.4% during the first quarter. BlackRock Inc. now owns 5,443,837 shares of the company’s stock worth $38,052,000 after purchasing an additional 229,373 shares during the period. Vitruvian Partners LLP lifted its holdings in shares of MaxCyte by 15.0% during the second quarter. Vitruvian Partners LLP now owns 5,043,356 shares of the company’s stock worth $23,855,000 after purchasing an additional 657,686 shares during the period. Vanguard Group Inc. lifted its holdings in shares of MaxCyte by 4.0% during the first quarter. Vanguard Group Inc. now owns 3,284,596 shares of the company’s stock worth $22,958,000 after purchasing an additional 126,906 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in shares of MaxCyte by 26.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,367,838 shares of the company’s stock worth $11,200,000 after purchasing an additional 495,641 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of MaxCyte by 67.3% during the second quarter. Millennium Management LLC now owns 2,355,086 shares of the company’s stock worth $11,140,000 after purchasing an additional 947,104 shares during the period. 66.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, BTIG Research reduced their target price on MaxCyte to $9.00 in a report on Tuesday, November 15th.

Insider Buying and Selling at MaxCyte

In other news, EVP Thomas M. Ross sold 9,153 shares of the firm’s stock in a transaction on Wednesday, January 4th. The stock was sold at an average price of $5.07, for a total value of $46,405.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Thomas M. Ross sold 9,153 shares of the firm’s stock in a transaction on Wednesday, January 4th. The stock was sold at an average price of $5.07, for a total value of $46,405.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Douglas Doerfler sold 10,613 shares of the firm’s stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $5.13, for a total value of $54,444.69. Following the completion of the transaction, the chief executive officer now owns 333,197 shares of the company’s stock, valued at approximately $1,709,300.61. The disclosure for this sale can be found here. Over the last quarter, insiders sold 82,562 shares of company stock valued at $484,330. 5.11% of the stock is owned by company insiders.

MaxCyte Stock Performance

MaxCyte stock opened at $5.19 on Friday. MaxCyte, Inc. has a one year low of $3.36 and a one year high of $7.76. The business has a fifty day moving average of $5.61 and a two-hundred day moving average of $5.79. The company has a market cap of $530.57 million, a P/E ratio of -22.56 and a beta of 0.44.

MaxCyte (NASDAQ:MXCTGet Rating) last released its earnings results on Wednesday, November 9th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. MaxCyte had a negative return on equity of 9.12% and a negative net margin of 56.29%. The company had revenue of $10.64 million during the quarter, compared to the consensus estimate of $10.40 million. Sell-side analysts predict that MaxCyte, Inc. will post -0.28 EPS for the current year.

MaxCyte Company Profile

(Get Rating)

MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

See Also

Want to see what other hedge funds are holding MXCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MaxCyte, Inc. (NASDAQ:MXCTGet Rating).

Institutional Ownership by Quarter for MaxCyte (NASDAQ:MXCT)

Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.